5,215 China Trials in 2025 Cost 60% Less Than US: Security Risks Loom

For healthcare leaders and policymakers, China’s explosive growth in clinical trials—5,215 recorded in 2025—poses both an opportunity and a threat. While dramatically lower trial costs could accelerate drug development and reduce healthcare spending, the heavy reliance on China-based research raises red flags about data security, intellectual property, and supply chain vulnerabilities in an era of geopolitical tension.

China's clinical drug trial registrations reached an all-time high of 5,215 in 2025, more than doubling the figure from 2020, according to a report released by the National Medical Products Administration (NMPA) on Monday, June 22, 2026. This explosive growth underscores Beijing's strategic prioritization of biotechnology as a pillar of economic growth and national competitiveness. The data reveals a maturing ecosystem: 57.5% of all trials were for novel drugs—an 18% year-on-year increase—while the rest were bioequivalence studies. Chinese companies or institutions initiated or funded 93% of all registered trials, and 92% were conducted entirely within China, signaling a remarkably self-sufficient R&D infrastructure.

“

The data reveals a maturing ecosystem: 57.5% of all trials were for novel drugs—an 18% year-on-year increase—while the rest were bioequivalence studies.

The geographic concentration in Beijing, Shanghai, Guangdong, and Jiangsu aligns with existing biotech hubs that benefit from dense academic centers, venture capital, and government backing. Therapeutic areas reflect global health priorities: cancer treatments dominated new drug trials, followed by dermatologic, ophthalmic, and otolaryngologic conditions, hormonal/metabolic disorders like diabetes and thyroid disease, and infectious disease vaccines. Notably, traditional Chinese medicine trials focused on respiratory and neuropsychiatric conditions, indicating the government's dual push in both modern and traditional medicine.

This surge has profound implications for the global pharmaceutical landscape. Data presented at the Outsourcing in Clinical Trials conference in California in February 2026 showed that clinical trials in China cost 50–60% less than in the US and are completed more quickly. Multinational drugmakers have increasingly outsourced trials to Chinese sites to reduce costs and accelerate timelines. However, this reliance introduces vulnerabilities: intellectual property theft, data integrity concerns, and the potential for weaponization of drug supply chains in geopolitical standoffs.

Washington has taken notice. While the SCMP article's title references US security concerns, the body text was truncated; nonetheless, the national security dimension is well-established in recent policy discourse. The US has already restricted Chinese access to certain biotechnologies and data, and legislation akin to the BIOSECURE Act has been proposed to decouple medical supply chains from China. The record 2025 numbers will likely intensify calls for greater oversight of foreign participation in US clinical trials and drug applications that rely on overseas data.